Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience

Abdul Muqtadir Abbasi, Mohammad Usman Shaikh, Natasha Ali, Maria Khan, Salman Muhammad Soomar

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

Original languageEnglish
Article number100295
JournalLeukemia Research Reports
Volume17
DOIs
Publication statusPublished - Jan 2022

Keywords

  • Complete resposne
  • Eltrombopag
  • Immune thrombocytopenia
  • Platelet response
  • Severe aplastic anemia

Fingerprint

Dive into the research topics of 'Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience'. Together they form a unique fingerprint.

Cite this